LG Chem Anti-LILRB1 Antibody Patent US12606620B2

The USPTO issued Patent US12606620B2 to LG CHEM, LTD. for an anti-LILRB1 antibody demonstrating increased specificity for LILRB1, along with antigen-binding fragments of the antibody. The patent specifically covers therapeutic applications of the antibody in cancer treatment. The patent contains 17 claims and was filed on July 27, 2021.

For pharmaceutical companies, biotechnology firms, and research institutions developing immunotherapies targeting LILRB1 or related immune checkpoint pathways, this patent represents a potential freedom-to-operate consideration. Any parties pursuing similar antibody technologies against LILRB1 may need to evaluate licensing options or design-around strategies to avoid infringement on the granted claims.